Search results for: 'biologics da1a management'

10 May 2023  |  Global  |  Market Research

Growth Opportunities in the Biologics Contract Development and Manufacturing Organization Sector

Value Chain Expansion to Support Next generation Biologics Drives Future Growth Potential

Infographics

×

This research service provides an overview of the global biologics contract development and manufacturing organization (bio-CDMO) market and a 6-year market revenue forecast (2023 to 2028). The geographic scope covers three key regions, namely North America (NA); Europe; and Asia-Pacific (APAC). The report offers a detailed segment analysis of...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

05 Sep 2022  |  Global  |  Market Research

Global Agricultural Biologicals Market, Forecast to 2030

Changes in Regulatory Environment to Fuel Growth Opportunities in the Biopesticides and Biostimulants Sectors

Infographics

×

Key Issues Addressed

This research service provides qualitative and quantitative analyses of agricultural biologicals by segment: biopesticides and biostimulants. The biopesticides segment is divided by type (bioherbicides, bioinsecticides, biofungicides, and bionematicides) and by source (microbials and biochemicals). The biostimulants segment is divided only by typ...

There have been increasing incidences of rare ophthalmic diseases (e.g., retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis) and prevalent diseases (e.g., age-related macular degeneration [AMD], geographic atrophy). While clinicians have used small molecules as the conventional therapeutic modality to manage these diseases, the urg...

20 Nov 2017  |  North America  |  Market Research

Global Biologics Market—Companies-to-Action

Biopharma Companies are Increasingly Collaborating with CDMOs, CROs, and Digital and Medical Equipment Companies for Biologics Discovery and Development

Infographics

×

This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the gro...

Just as global markets show signs of moving on from the disruptions caused by COVID-19, the French economy now faces a period of high inflation and low economic growth. High inflation will act as a tailwind for rising prices and revenues. While this is expected to drive revenue expansion, it will increase costs and put pressure on margins. Franc...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across recent developments for intelligent drug discovery solutions, precision oncology and novel biologics. The TOE also comprises innovations across stem cell therapies and radiotherapies.The Life Science, Health & Wellness TOE will feature d...

Biologics, particularly peptide and protein therapies, are a rapidly growing therapeutic area because they can target complex biological pathways with high efficacy. These therapies are becoming important in oncology, metabolic disease, and autoimmune conditions supported by the growing global disease burden and growth in areas such as GLP-1s and m...

Biological age tracking is emerging as a complementary approach to understanding human health, offering a more nuanced assessment of physiological state than chronological age alone. This report examines the evolving landscape of biological aging platforms, with a focus on molecular and omics-based technologies including epigenetic, proteomic, tran...